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Toxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse, France
Resistance in canine pathogenic staphylococci is necessitating re-evaluation of the
current antimicrobial treatments especially for biofilm-associated infections. Long,
repeated treatments are often required to control such infections due to the tolerance
of bacteria within the biofilm. To comply with the goal of better antibiotic stewardship in
veterinary medicine, the efficacies of the available drugs need to be directly assessed
on bacterial biofilms. We compared the activities of amoxicillin, cefalexin, clindamycin,
doxycycline, and marbofloxacin on in vitro biofilms of Staphylococcus pseudintermedius
and Staphylococcus aureus. Exposure of biofilms for 15 h to maximum concentrations
of the antibiotics achievable in canine plasma only reduced biofilm bacteria by 0.5–
2.0 log10 CFU, compared to the control, except for marbofloxacin which reduced
S. aureus biofilms by 5.4 log10 CFU. Two-antibiotic combinations did not improve, and
even decreased, bacterial killing. In comparison, 5 min-exposure to 2% chlorhexidine
reduced biofilms of the two tested strains by 4 log10 CFU. Our results showed that
S. pseudintermedius and S. aureus biofilms were highly tolerant to all the drugs
tested, consistent with the treatment failures observed in practice. Under our in vitro
conditions, the use of chlorhexidine was more efficacious than antimicrobials to reduce
S. pseudintermedius biofilm.
Keywords: biofilm, antimicrobial activity, Staphylococcus aureus, Staphylococcus pseudintermedius, veterinary
antimicrobials
INTRODUCTION
The emergence of methicillin-resistant Staphylococcus pseudintermedius (MRSP) in dogs and
the zoonotic risk of staphylococcal infections in pets are highlighting the urgent need for
improved antimicrobial stewardship to reduce the often extremely long and repeated treatments
for pyoderma in veterinary medicine (Guardabassi et al., 2004; Van Hoovels et al., 2006; Pompilio
et al., 2015).
Staphylococcus pseudintermedius, an opportunistic pathogen of dogs, is the leading cause of
skin and ear infections (Hillier et al., 2014). Although, Staphylococcus aureus and Staphylococcus
schleiferi can be isolated on dogs, these pathogens are rarely associated with pyoderma (Frank
and Loeﬄer, 2012). Most animals suffering from staphylococcal skin infection have reduced
immunity associated with alterations of the skin barrier or underlying diseases that may be
difficult to diagnose and cure. Pyoderma infections are therefore the principal reason for
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antimicrobial use in small animal practice (Rantala et al., 2004)
and predispose to long and repeated antimicrobial treatments
(Hillier et al., 2014). Conventional treatment of superficial and
deep canine staphylococcal pyoderma has been based on systemic
antibacterial administration for 3–4 weeks sometimes combined
with a topical treatment (Loeﬄer et al., 2007; Frank and Loeﬄer,
2012; Borio et al., 2015).
Biofilm formation is known to be a major virulence factor
in several Staphylococcus spp. including S. pseudintermedius.
Biofilms are groups of bacterial cells which adhere to the surfaces
of living tissues or artificial materials and are covered by a
self-produced extracellular polysaccharide (EPS) matrix (Davies,
2003). This is a natural survival mode for bacterial cells, distinct
from that of planktonic cells, and formed in adaptation to
environmental pressures in the long-term evolutionary process
(Costerton et al., 1999). After biofilm formation, the infectious
bacterial antigens induce the production of large quantities
of antibodies which are able to combat planktonic bacteria,
but remain ineffective against bacteria inside the biofilm,
due to the protective matrix (Costerton et al., 1999). In
addition, the bacteria inside biofilms are highly tolerant to
antibiotics and even though the underlying mechanism has
not been completely elucidated, phenotypic variation leading
to a “persister” status has been reported (Davies, 2003; Van
Hoovels et al., 2006; Yang et al., 2015). As stated by others, the
high prevalence of these persister bacteria in biofilms precludes
the direct use of standard susceptibility results to predict
clinical efficacy on biofilm-associated infections (Claessens et al.,
2015).
The drug susceptibility of a bacterial strain is classically
determined from the minimum inhibitory concentration
(MIC) or by antimicrobial susceptibility testing (AST). These
determinations are done in laboratory on planktonic bacteria
during their exponential growth phase. It has been demonstrated,
however, that antibiotic activity can be drastically reduced (and
not therefore predictable by standard AST), if the bacterial
inoculum is high (Ferran et al., 2014) or when the growth rate or
metabolism of the bacteria is reduced, as in biofilms (Costerton
et al., 1999; Davies, 2003; Guardabassi et al., 2004). Thus, to
propose a more efficacious treatment for canine pyoderma, which
is a biofilm-associated infection, the activity of antimicrobial
drugs needs to be directly investigated on the bacterial biofilms.
The veterinary guidelines recommend amoxicillin/clavulanic
acid, cefalexin or clindamycin as first-line empirical agents
for systemic antibiotic therapy (Hillier et al., 2014). Third
generation cephalosporins, doxycycline, fluoroquinolones,
chloramphenicol, aminoglycosides, and rifampicin are classified
as second tier drugs (Hillier et al., 2014). Whatever the drug, the
recommended treatment duration usually exceeds 3 weeks to
prevent relapses (Beco et al., 2013; Hillier et al., 2014). This is a
cause of concern, in terms of the prudent use of antimicrobials,
as treatment duration is a major factor contributing to the
emergence of resistances (Rubinstein and Keynan, 2013). In
order to contribute to the improvement of in vivo treatment,
we assessed the antimicrobial activity of first and second-tier
drugs on in vitro biofilms formed by S. pseudintermedius or
S. aureus.
MATERIALS AND METHODS
Test Strains
A S. aureus strain (HG001), derived from NCTC 8325, and
S. pseudintermedius ATCC 49444 were used.
Antimicrobial Agents
Amoxicillin, cefalexin, clindamycin, and doxycycline were
purchased from Sigma-Aldrich. Marbofloxacin was kindly
provided by Vetoquinol. Antibiotics were dissolved in pure water,
with NaOH added to amoxicillin and cefalexin.
The tested drug concentrations were selected to be equal
or slightly above the total maximum concentration attained
in canine serum after administration of the approved or
recommended standard doses (Silley et al., 1988; Kung and
Wanner, 1994; Schneider et al., 1996; Batzias et al., 2005;
Hillier et al., 2014; KuKanich and KuKanich, 2015). The tested
concentrations were 5 µg/mL for marbofloxacin, 10 µg/mL for
clindamycin and doxycycline, 20 µg/mL for amoxicillin, and
50 µg/mL for cefalexin.
Chlorhexidine was purchased as chlorhexidine digluconate
(Hibitan Irrigation 20%ND, MSD, France).
Antimicrobial and Chlorhexidine
Susceptibility
The MIC were determined in triplicate by microdilution method
as described in the CLSI reference methods (CLSI, 2006).
Biofilm Formation
The bacterial biofilm was produced in 6-well plates (polystyrene).
A bacterial colony from an overnight culture of S. aureus or
S. pseudintermedius was diluted in Mueller-Hinton (MH) broth
to obtain a bacterial suspension containing 105 CFU/mL. Each
well of 6-well plates (polystyrene) was filled with 4 mL of bacterial
suspension and incubated at 37◦C for 7 h without shaking to
allow biofilm formation. At this time point, the planktonic and
biofilm bacteria in three control wells were counted to assess
biofilm status at the time of drug addition.
Antibiotic Activity Testing
After 7 h of incubation, the medium was renewed to avoid
nutrient deficiency. To do that, three milliliters of the suspension
only containing the planktonic bacteria were carefully removed
from each well, and centrifuged for 10 min (3000 g, 20◦C).
The supernatant was discarded and 3.5 mL of fresh MH broth
was added to the bacterial pellet. After shaking, the suspension
containing the planktonic bacteria was then carefully returned to
the original wells to preserve the 7 h-old biofilm. After incubation
for 1 h, 45 µL of antibiotic solution or MH (control) was added
and the prepared plates were incubated overnight before bacterial
counting. The antibiotic drugs were tested alone or in pairs. Each
experiment was performed in triplicate.
Chlorhexidine Activity Testing
As the addition of chlorhexidine to MH broth leads to
precipitation, chlorhexidine efficacy was assessed with a different
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protocol. After 7 h of incubation, the total bacterial suspension
only containing the planktonic bacteria was collected. One mL of
water was added to cover the 7 h-old biofilm while the suspension
was centrifuged (10 min, 3000 g, 20◦C). The supernatant was then
discarded and the pellet resuspended in water before returning
the planktonic bacteria. Chlorhexidine digluconate was added to
the wells to obtain final concentrations of 2%. Three wells without
chlorhexidine were used as control. After 5 min exposure, the
biofilm and planktonic bacteria were counted.
Suspension was removed and rinsed twice in water before
counting in NaCl 0.9%. The biofilm bacteria were counted as
described in the antimicrobial drug protocol. Due to the change
of medium from MH to water, this experiment had its own
control wells without any drug.
Quantification of Planktonic and Biofilm
Bacteria
Planktonic Bacteria
The suspension containing planktonic bacteria in each well was
carefully removed and the planktonic bacteria were counted
after successive 10-fold dilutions on tryptic soy agar plates. The
colonies were counted after overnight incubation at 37◦C. The
limit of quantification was 100 CFU/mL. Bacterial reductions
were calculated as the differences between the bacterial counts
in control wells and the bacterial counts after exposure to
antimicrobials or biocide.
For experiments with chlorhexidine, the suspension was
rinsed twice in water to stop biocide activity before counting.
Biofilm Bacteria
The biofilm bacteria remaining in the wells after the suspension
removal were rinsed twice with 4 mL NaCl 0.9%. After the final
rinse, 6 mL NaCl 0.9% was added to each well. The bacteria in the
liquid portion were counted in each well before and after 15 min-
ultrasounds. The colonies obtained after plating successive 10-
fold dilutions on tryptic soy agar plates were counted after
overnight incubation. The difference in bacterial counts before
and after the ultrasounds was considered to represent the “pure”
biofilm bacteria. The limit of quantification was 600 CFU.
Bacterial reductions were calculated as the differences between
the biofilm bacteria counts in control wells and the biofilm
bacteria counts after exposure to antimicrobials or biocide.
RESULTS
Antimicrobial Susceptibility Testing
The MIC of amoxicillin, cefalexin, clindamycin, doxycycline,
marbofloxacin, and chlorhexidine for the S. aureus and
S. pseudintermedius strains and the test concentrations are given
in Table 1. According to the CLSI breakpoints, both strains were
susceptible to clindamycin, doxycycline, and marbofloxacin. Both
strains were resistant to amoxicillin (MIC equal to the “resistant”
breakpoint). For cefalexin, S aureus was classified as resistant and
S. pseudintermedius as susceptible. The MIC for a given drug
differed by less than two dilutions (fourfold) for both two strains.
The test concentrations were at least 20-fold higher than the MIC
except for cefalexin and S. aureus (sixfold).
Assessment of the Effects of Antibiotics
on Biofilms In vitro
After incubation of S. pseudintermedius for 7 h, the suspension
contained 8.11± 0.33 log10 CFU/mL and the biofilm 7.89± 0.20
log10 CFU. For S. aureus at the same time point, the suspension
contained 7.32 ± 0.04 log10 CFU/mL and the biofilm contained
8.17± 0.14 log10 CFU.
The antimicrobial drugs were added at that time and the
bacteria were again counted after 15 h. The numbers of bacteria in
the control wells (without any drug) increased slightly overnight.
For S. pseudintermedius, the populations increased by 0.71 log10
CFU /mL in the suspension and by 0.85 log10 CFU in the biofilm.
For S aureus, the increases were 1.15 log10 CFU/mL and 0.30 log10
CFU, respectively.
The reductions in bacterial counts, after 15 h of drug
exposure, in the suspension and in the biofilm for all the tested
antibiotics, compared to the control, are given in Tables 2 and 3
and represented in Figures 1 and 2 for S. aureus and
S. pseudintermedius, respectively. All tested antibiotics reduced
the bacterial counts in the suspension and biofilm of both strains
even if some antibiotics showed extremely low activity. For
most of the antibiotics, the obtained reduction of the bacterial
population was less than 2 log10 CFU. Amoxicillin, cefalexin
and doxycycline reduced S. pseudintermedius bacteria by only
0.67 to 0.85 log10 CFU/mL in suspension and by 0.55–0.61
log10 CFU in biofilm. For S. aureus exposed to the same three
antibiotics, the reduction ranged from 0.73 to 1.10 log10 CFU/mL
in suspension and from 0.50 to 0.57 log10 CFU in biofilm.
Clindamycin and marbofloxacin exhibited higher activities than
the other drugs, especially against S. aureus. Clindamycin
reduced S. pseudintermedius biofilm by 0.75 log10 CFU and
S aureus biofilm by 1.84 log10 CFU. For marbofloxacin, the
reduction attained 2.9 and 5.4 log10 CFU for S. pseudintermedius
and S. aureus biofilms respectively. Marbofloxacin was the only
antibiotic which eradicated S. aureus in suspension and gave a
final bacterial load of only 3.09 log10 CFU in the biofilm.
As none of the tested antibiotics showed bactericidal activity
against S. pseudintermedius, we then tested all possible two-drug
combinations, except for amoxicillin and cefalexin which share
the same bacterial target. The reductions in bacterial counts
with the different combinations are shown in Tables 2 and 3.
The results obtained by combining the most efficacious drugs,
clindamycin and marbofloxacin, are also given in Figure 3.
All combinations resulted in less bacterial eradication than
the most efficacious of the two drugs tested alone, except for
three specific cases where the combination was slightly better.
Bacterial reduction in the S. aureus biofilm was 0.25 log10 CFU
higher with both the clindamycin–amoxicillin and clindamycin–
cefalexin combinations than with clindamycin alone. For
S. pseudintermedius, bacterial reduction in the suspension and
biofilm was higher, by 0.1 log10 CFU/mL and 0.5 log10 CFU
respectively, with the marbofloxacin–amoxicillin combination
than with marbofloxacin alone.
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TABLE 1 | CLSI and chlorhexidine breakpoints (Horner et al., 2012; CLSI, 2016), tested antibiotic or biocide concentrations on in vitro biofilms and MIC of
the antibiotic drugs for the selected strains of Staphylococcus aureus and Staphylococcus pseudintermedius.
CLSI breakpointsa (mg/L) Tested concentrations S. aureus MIC S. pseudintermedius MIC
Antibiotic S I R (mg/L) (mg/L) (mg/L)
Amoxicillin 0.25 0.5 20 0.5 0.5
Cefalexin 2 4 8 50 8 2
Clindamycin 0.5 1–2 4 10 0.064 0.064
Doxycycline 0.125 0.25 0.5 10 0.032 0.125
Marbofloxacin 1 2 4 5 0.125 0.25
Chlorhexidine 4 118b 0.5 0.5
aFor amoxicillin, the CLSI breakpoints of ampicillin were used. For cefalexin, the CLSI breakpoints of cefazolin and cefalothin were used. For chlorhexidine, the 4 µg/mL
breakpoint which is not a CLSI breakpoint was reported by Horner et al., 2012. b118 mg/L chlorhexidine correponds to 200 mg/L chlorhexidine digluconate.
TABLE 2 | Bacterial reductions of S. aureus suspension (in log10 CFU/mL)
and biofilm (in log10 CFU) after 15-h exposure to one drug or to a
two-drug combination.
Suspension AMX CFX CLI DOX MAR CHD
AMX −0.86
CFX NA −0.73
CLI −2.76 −2.54 −3.03
DOX −1.09 −0.98 −1.62 −1.09
MAR −4.18 −4.30 −3.10 −2.82 −6.47
CHD NA NA NA NA NA −5.20
Biofilm AMX CFX CLI DOX MAR CHD
AMX −0.57
CFX NA −0.50
CLI −2.09 −2.02 −1.84
DOX −0.31 −0.49 −0.71 −0.57
MAR −3.23 −3.65 −2.08 −2.01 −5.38
CHD NA NA NA NA NA −3.96
For chlorhexidine, bacteria were only exposed for 5 min. AMX, amoxicilin;
CFX, cefalexin; CLI, clindamycin; DOX, doxycycline; MAR, marbofloxacin; CHD,
chlorhexidine; NA, not assessed. Bacterial reductions below 1.5 log10 CFU/mL are
in gray, between 1.5 and 3 log10 CFU/mL in yellow, between 3 and 4 log10 CFU/mL
in light green and higher than 4 log10 CFU/mL in dark green.
Assessment of the Effects of
Chlorhexidine on Biofilms In vitro
Separate experiments were conducted to assess the activity of
chlorhexidine on biofilms. We first checked that the use of water
to dilute chlorhexidine did not affect the biofilms formed after 7 h
incubation. The bacterial counts in the biofilms of control wells
incubated for 5 min in water and rinsed twice with water were
7.24 ± 0.25 log10 CFU for S. pseudintermedius and 7.44 ± 0.15
log10 CFU for S. aureus, corresponding to differences of less
than 1 log10 CFU (0.65 and 0.73 log10 CFU), as compared
to control biofilms in the experiments with antibiotics. After
5 min exposure to 2% chlorhexidine, the mean reduction of
S. aureus and S. pseudintermedius biofilms was 4 log10 CFU and
eradication was attained in half of the experiments. All bacteria
in the suspension were eradicated but the time of exposure to
chlorhexidine greatly exceeded 5 min due to the time required
for centrifugation before the first rinse.
TABLE 3 | Bacterial reductions of S. pseudintermedius suspension (in
log10 CFU/mL) and biofilm (in log10 CFU) after 15-h exposure to one drug
or to a two-drug combination.
Suspension AMX CFX CLI DOX MAR CHD
AMX −0.68
CFX NA −0.73
CLI −1.02 −0.88 −1.23
DOX −0.67 −0.68 −0.91 −0.85
MAR −2.94 −2.40 −2.03 −2.34 −2.83
CHD NA NA NA NA NA −5.60
Biofilm AMX CFX CLI DOX MAR CHD
AMX −0.61
CFX NA −0.58
CLI −0.72 −0.48 −0.75
DOX −0.62 −0.46 −1.24 −0.55
MAR −2.52 −1.86 −1.27 −1.62 −2.02
CHD NA NA NA NA NA −3.92
For chlorhexidine, bacteria were only exposed for 5 min. AMX, amoxicilin;
CFX, cefalexin; CLI, clindamycin; DOX, doxycycline; MAR, marbofloxacin; CHD,
chlorhexidine; NA, not assessed. Bacterial reductions below 1.5 log10 CFU/mL are
in gray, between 1.5 and 3 log10 CFU/mL in yellow, between 3 and 4 log10 CFU/mL
in light green and higher than 4 log10 CFU/mL in dark green.
DISCUSSION
In the light of increasing multidrug resistance in zoonotic
staphylococci, optimizing the therapeutic strategies utilized for
canine pyoderma has become a human health issue. Although,
most cases treated for S. pseudintermedius infection ultimately
respond to empirical treatments, the duration of such treatments
often exceeds 1 month implying a sustained selective pressure
which favors the emergence of resistance in staphylococci and in
other commensal bacteria (Hillier et al., 2014). As the bacteria
become organized in a biofilm containing many persister cells
tolerant to antibiotics (Yang et al., 2015), the predictive value
of AST in determining the clinical outcome is very limited
and direct assessment of the antibiotic’s activity on biofilms is
required. In this study, we showed that most first and second-
line antibiotics recommended for pyoderma display very low
antibacterial activity on in vitro S. pseudintermedius biofilms.
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FIGURE 1 | Bacterial reductions (mean ± SD) of Staphylococcus
aureus suspension (gray bars, in log10 CFU/mL) and biofilm (black
bars, in log10 CFU) after 15-h exposure to amoxicillin (AMX), cefalexin
(CFX), clindamycin (CLI), doxycycline (DOX), or marbofloxacin (MAR)
or after 5- min exposure to chlorhexidine (CHD).
FIGURE 2 | Bacterial reductions (mean ± SD) of Staphylococcus
pseudintermedius suspension (gray bars, in log10 CFU/mL) and
biofilm (black bars, in log10 CFU) after 15-h exposure to amoxicillin
(AMX), cefalexin (CFX), clindamycin (CLI), doxycycline (DOX), or
marbofloxacin (MAR) or after 5- min exposure to chlorhexidine (CHD).
In this study, S. pseudintermedius and S. aureus biofilms were
tested in vitro and no account was taken of the complexity of
an in vivo infection, that involves multiple factors such as the
immune system, the presence of necrotic or scar tissues and
possible hidden intracellular bacteria. Nevertheless, measuring
antimicrobial activity on a bacterial population embedded in
a biofilm and including a high proportion of persisters is
likely to be more efficient in predicting the ultimate clinical
outcome than standard AST performed on planktonic bacterial
populations in exponential growth phase. We believe that our
experiments, even if conducted with one strain per species, could
be considered as a first step in the process of drug selection and
drug regimen optimization for biofilm-associated infections in
veterinary medicine.
After incubation without drugs for 7 or 24 h, more than 7.8
log10 CFU of the bacteria (S. pseudintermedius and S. aureus)
were found in the biofilm. This rapid development was also
reported in a study showing that S. pseudintermedius could
form biofilm within 24 h in vitro with no difference between
methicillin-susceptible and methicillin-resistant strains (Singh
et al., 2013). Another study by Pompilio et al. (2015) revealed that
S. pseudintermedius was able to form a well-structured biofilm
consisting of multilayered, mushroom-shaped microcolonies
embedded in an abundant EPS matrix. We decided to qualify
the activities of our test drugs by examining their efficacies
on a “young” biofilm produced after incubation for 7 h. No
reduction of biofilm had been observed when the effects of the
same antimicrobials had been tested on a 24 h-old biofilm (data
not shown). This suggests that an environmental or phenotypic
change occurred between 7 and 24 h, which had no effect on the
numbers of bacteria but was able to modify their susceptibility to
drugs.
We tested some of the first- and second-line drugs
recommended for the systemic treatment of pyoderma in
veterinary medicine (Hillier et al., 2014). We exposed S. aureus
and S. pseudintermedius biofilms for 15 h to concentrations equal
or slightly above the peak concentrations observed in vivo in
dogs during a recommended dosage regimen. Taking plasma
protein binding into account, the actual test concentrations in
our system were higher than the active free in vivo concentrations
in dogs, especially for doxycycline (90% bound), and we likely
assessed the highest possible antibacterial activity of each drug
in dogs. Even so, all of the drugs tested exhibited very low
killing activity on S. pseudintermedius and S. aureus biofilms,
except for the fluoroquinolone, marbofloxacin on S. aureus.
Also, by comparing these two staphylococci species, we found
that antibacterial activity against S. pseudintermedius tended
to be lower than against S. aureus. For example, although
the MIC determination classified both species as susceptible
to clindamycin and marbofloxacin, bacterial killing was lower
for S. pseudintermedius than for S. aureus. Then, for cefalexin,
even though S. pseudintermedius was classified as susceptible
and S. aureus as resistant, the efficacy against both strains
was similarly low. This lower activity of antibiotic drugs on
S. pseudintermedius than on S. aureus, which is not predictable
by susceptibility testing, is consistent with the difficulty of
eradicating pyoderma in dogs. It also implies that a human
infection with this zoonotic bacterial species would be hard to
eradicate. One study with a S. pseudintermedius strain isolated
from a human infection demonstrated that, at concentrations
128-fold higher than the MIC, none of the antibiotics tested
(which included vancomycin and linezolid) was able to eradicate
a 48-h old biofilm, except for rifampicin (Pompilio et al.,
2015). Interestingly, similar observations were reported with
Staphylococcus epidermidis, an opportunistic human pathogen
responsible for the vast majority of nosocomial catheter-related
blood stream infections (Claessens et al., 2015). Even though
the strain of S. epidermidis is classified as susceptible to
vancomycin, based on the MIC determination, killing activity
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FIGURE 3 | Bacterial reductions (mean ± SD) of S. aureus (A) or S. pseudintermedius (B) suspension (gray bars, in log10 CFU/mL) and biofilm (black
bars, in log10 CFU) after 15-h exposure to marbofloxacin (MAR) and clindamycin (CLI) alone or in combination with amoxicillin (AMX), cefalexin
(CFX), or doxycycline (DOX).
against a biofilm of the same bacteria was poor (Claessens et al.,
2015).
By systematically comparing the bacterial counts in
suspension and biofilm, we found that the difference between
the two populations was never more than 1 log10 CFU/mL
even after exposure to antimicrobial drugs, whereas planktonic
bacteria are supposed to be much more readily killed by drugs
(Bjarnsholt et al., 2013). This suggests the possible existence of
an equilibrium between planktonic and biofilm bacteria, and
that bacteria can be released from a biofilm into suspension
during antibiotic exposure or that planktonic bacteria associated
with a biofilm are not phenotypically the same as the planktonic
bacteria exposed to drugs during a MIC determination.
Although amoxicillin, cefalexin and marbofloxacin are all
classified as bactericidal in our experiments, marbofloxacin
exhibited far greater activity than amoxicillin or cefalexin. This
difference in bacterial killing may be due to the fact that
fluoroquinolones can kill non-dividing bacteria whereas beta-
lactam drugs cannot (Drlica et al., 2008). We showed in our
system that the bacterial population at the time of drug challenge
exceeded 7.8 log10 CFU in biofilm and 7.3 log10 CFU/mL in
suspension and that very little growth occurred in the control
wells between 7 and 24 h. This indicates that the bacterial
population was in a stationary phase which would favor the
activity of marbofloxacin over that of other drugs. The greater but
limited in vitro activity of marbofloxacin on S. pseudintermedius,
as compared to other drugs in our model, is difficult to connect
with clinical outcomes due to the fact that blinded randomized
controlled investigations of systemic antimicrobial efficacies in
the treatment of canine pyoderma are very rare (Frank and
Loeﬄer, 2012; Summers et al., 2012). However, the generally low
antimicrobial activity of the tested drugs would probably be a
main factor explaining the need for treatments of long duration
to obtain a clinical cure of canine pyoderma and to prevent
relapse.
In view of the low antibacterial effects of the first and
second-line drugs used in monotherapy, we then assessed
the efficacy of two-drug combinations, as is currently being
applied in human medicine (Romling and Balsalobre, 2012;
Claessens et al., 2015). The addition of a second drug
had very slight beneficial or even negative effect on the
bacterial killing. According to Jawetz laws (Jawetz, 1968, 1975),
these results could perhaps have been anticipated for the
combination of bactericidal and bacteriostatic drugs as for
example the combination of doxycycline and cefalexin. However,
the reduced bacterial activity of marbofloxacin after adding
another bactericidal drug, such as amoxicillin or cefalexin, was
quite unexpected even though similar results have recently
been reported by Yang et al. (2015). Indeed, these authors
showed that the efficacy of a combination of ciprofloxacin and
vancomycin on S. epidermidis biofilm was less than that of
ciprofloxacin alone (Yang et al., 2015). It can be hypothesized
that the increased bacterial stress conferred by two drugs
resulted in the formation of persister cells (Lewis, 2007).
Until sufficient data for each possible combination becomes
available, this therapeutic strategy should probably be not
recommended.
The poor activity of drugs used singly in our study and
the absence of additive activity when used in combination
suggest that systemic treatments alone are not the best way to
target Staphylococcus spp., especially S. pseudintermedius. For this
reason, we also explored an alternative treatment, i.e., external
use of chlorhexidine. In our system, a 2% concentration of
chlorhexidine was found to kill biofilm bacteria after 5 min
exposure. Biofilm bacteria of both strains were eradicated in 1
or 2 wells out of 3. These in vitro results may suggest that a
topical shampoo might be more effective than most systemic
treatments, the limiting condition being that the application
of a chlorhexidine shampoo should come in contact with all
the bacteria (treatment of entire surface with no restriction to
diffusion (hairs, crusts) in order to attain the bacteria). This
excellent efficacy of chlorhexidine is in agreement with another
in vitro study which showed that a 4% solution of chlorhexidine
killed S. pseudintermedius in less than 1 min (Lloyd and Lamport,
1999). Several clinical studies have also provided evidence of
the efficacy of chlorhexidine at least for superficial pyoderma
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(Bryan et al., 2012; Mueller et al., 2012) and similar efficacy
was observed when a topical chlorhexidine digluconate shampoo
treatment applied twice weekly for 4 weeks was compared with a
systemic administration of amoxicillin–clavulanic acid 25 mg/kg
twice daily for 4 weeks (Borio et al., 2015). In addition to
the killing activity of chlorhexidine on pathogenic bacteria, a
topical treatment has the advantage of not impacting the digestive
commensal flora and therefore reducing the selection pressure for
resistance in this microbiota.
Although, we did not investigate the development of
resistance in the targeted staphylococci all of the tested
antibiotic or biocide treatments can potentially induce resistance.
The proportion of Methicillin Resistant S. pseudintermedius
(MRSP) among S. pseudintermedius isolates from clinical
infections in the USA and Europe has risen since 2000
(Frank and Loeﬄer, 2012) and a link between antimicrobial
treatments within 30 days and MRSP infections has been
identified in dogs (Weese et al., 2012). Biocide resistances
can also develop during chlorhexidine treatment (Johnson
et al., 2015). Resistance to chlorhexidine can be conferred
by carriage of qac A/B or smr genes conding for eﬄux
pumps. Interestingly, one study reported that, among 247
strains, the qac A/B and smr positive bacteria were more often
resistant to some antimicrobial drugs including methicillin,
ciprofloxacin, and vancomycin than negative ones (McNeil
et al., 2015). This situation confirms the urgent need to
implement the stewardship for antibiotic use in veterinary
medicine.
CONCLUSION
This study provides further evidence that S. pseudintermedius
and S. aureus biofilms could be highly tolerant to veterinary
drugs. Taking in mind that further in vivo investigations on
efficacy and resistance development are required, the topical
administration of chlorhexidine could provide a promising
alternative strategy avoiding the long-term systemic use of
inefficacious antimicrobial drugs in animals.
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